Seamus Fernandez
Stock Analyst at Guggenheim
(4.29)
# 383
Out of 4,876 analysts
102
Total ratings
57.75%
Success rate
14.22%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $50 → $68 | $48.08 | +41.43% | 4 | Jun 24, 2025 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $17 | $6.30 | +169.84% | 1 | Jun 24, 2025 | |
| LLY Eli Lilly and Company | Reiterates: Buy | $936 | $784.38 | +19.33% | 16 | Jun 20, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $11.43 | +284.95% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $13.73 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $11.27 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $33.17 | +382.36% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $29.20 | +91.78% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $13.91 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $43.37 | - | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $137 → $130 | $79.24 | +64.06% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $38.68 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $62.26 | +12.43% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.97 | +168.01% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.93 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.59 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $13.70 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $21.35 | +134.19% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $46.80 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $68.53 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $120.32 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.03 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.46 | +3,598.63% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $21.02 | +114.08% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $70.05 | -45.75% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $24.36 | +55.99% | 3 | Jan 31, 2018 |
Cidara Therapeutics
Jun 24, 2025
Maintains: Buy
Price Target: $50 → $68
Current: $48.08
Upside: +41.43%
Amylyx Pharmaceuticals
Jun 24, 2025
Initiates: Buy
Price Target: $17
Current: $6.30
Upside: +169.84%
Eli Lilly and Company
Jun 20, 2025
Reiterates: Buy
Price Target: $936
Current: $784.38
Upside: +19.33%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $11.43
Upside: +284.95%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.73
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $11.27
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $33.17
Upside: +382.36%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $29.20
Upside: +91.78%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $13.91
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $43.37
Upside: -
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $79.24
Upside: +64.06%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $38.68
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $62.26
Upside: +12.43%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.97
Upside: +168.01%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.93
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.59
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $13.70
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $21.35
Upside: +134.19%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $46.80
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $68.53
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $120.32
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.03
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.46
Upside: +3,598.63%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $21.02
Upside: +114.08%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $70.05
Upside: -45.75%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $24.36
Upside: +55.99%